Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam C Yopp

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Annals of Surgery|June 14, 2023
Association Between Biliary Pathogens, Surgical Site Infection, and Pancreatic Fistula: Results of a Randomized Trial of Perioperative Antibiotic Prophylaxis in Patients Undergoing PancreatoduodenectomyRyan J Ellis, Brian C Brajcich, Kimberly A Bertens, et al.
Hepatology (Baltimore, Md.)|February 5, 2020
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With CirrhosisNicole E Rich, Binu V John, Neehar D Parikh, et al.
Journal of Translational Medicine|March 8, 2022
Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous populationJohn D Karalis, Lynn Y Yoon, Suntrea T G Hammer, et al.
Nature Communications|March 12, 2024
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialDavid Hsiehchen, Muhammad S Beg, Radhika Kainthla, et al.
Journal of Translational Medicine|September 13, 2024
Correction to: Lenvatinib inhibits the growth of gastric cancer patient‑derived xenografts generated from a heterogeneous populationsJohn D Karalis, Lynn Y Yoon, Suntrea T G Hammer, et al.
Lancet (London, England)|October 23, 2023
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Minshan Chen, Ann-Lii Cheng, et al.
Med (New York, N.Y.)|July 28, 2021
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosisNaoto Fujiwara, Masahiro Kobayashi, Austin J Fobar, et al.
Cancer Cell|November 15, 2017
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver CancerXuxu Sun, Sam C Wang, Yonglong Wei, et al.
Cancer Cell|January 10, 2018
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver CancerXuxu Sun, Sam C Wang, Yonglong Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2025
Presurgical ablative radiation is associated with local control and immune response in pancreatic cancerPeter Q Leung, Eslam A Elghonaimy, Ahmed M Elamir, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Annals of Surgery|June 14, 2023
Association Between Biliary Pathogens, Surgical Site Infection, and Pancreatic Fistula: Results of a Randomized Trial of Perioperative Antibiotic Prophylaxis in Patients Undergoing PancreatoduodenectomyRyan J Ellis, Brian C Brajcich, Kimberly A Bertens, et al.
Hepatology (Baltimore, Md.)|February 5, 2020
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With CirrhosisNicole E Rich, Binu V John, Neehar D Parikh, et al.
Journal of Translational Medicine|March 8, 2022
Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous populationJohn D Karalis, Lynn Y Yoon, Suntrea T G Hammer, et al.
Nature Communications|March 12, 2024
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialDavid Hsiehchen, Muhammad S Beg, Radhika Kainthla, et al.
Journal of Translational Medicine|September 13, 2024
Correction to: Lenvatinib inhibits the growth of gastric cancer patient‑derived xenografts generated from a heterogeneous populationsJohn D Karalis, Lynn Y Yoon, Suntrea T G Hammer, et al.
Lancet (London, England)|October 23, 2023
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Minshan Chen, Ann-Lii Cheng, et al.
Med (New York, N.Y.)|July 28, 2021
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosisNaoto Fujiwara, Masahiro Kobayashi, Austin J Fobar, et al.
Cancer Cell|November 15, 2017
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver CancerXuxu Sun, Sam C Wang, Yonglong Wei, et al.
Cancer Cell|January 10, 2018
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver CancerXuxu Sun, Sam C Wang, Yonglong Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2025
Presurgical ablative radiation is associated with local control and immune response in pancreatic cancerPeter Q Leung, Eslam A Elghonaimy, Ahmed M Elamir, et al.
Pageof 18